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Ove Andersen1,2, Charlotta Pisinger4,5 and Jesper Eugen-Olsen1,2*
Abstract
Background: The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor
(suPAR) is a strong predictor of disease development and premature mortality in the general population. Unhealthy
lifestyle habits such as smoking or unhealthy eating is known to elevate the suPAR level. We aimed to investigate
whether change in lifestyle habits impact on the suPAR level, and whether the resultant levels are associated with
mortality.
Results: Paired suPAR measurements from baseline- and the 5-year visit of the population-based Inter99 study
were compared with the habits of diet, smoking, alcohol consumption, and physical activity. Paired suPAR
measurements for 3225 individuals were analyzed by linear regression, adjusted for demographics and lifestyle
habits. Compared to individuals with a healthy lifestyle, an unhealthy diet, low physical activity, and daily
smoking were associated with a 5.9, 12.8, and 17.6% higher 5-year suPAR, respectively. During 6.1 years of
follow-up after the 5-year visit, 1.6% of those with a low suPAR (mean 2.93 ng/ml) died compared with 3.8%
of individuals with a high suPAR (mean 4.73 ng/ml), P < 0.001. In Cox regression analysis, adjusted for demographics
and lifestyle, the hazard ratio for mortality per 5-year suPAR doubling was 2.03 (95% CI: 1.22–3.37).
Conclusion: Lifestyle has a considerable impact on suPAR levels; the combination of unhealthy habits was associated
with 44% higher 5-year suPAR values and the 5-year suPAR was a strong predictor of mortality. We propose suPAR as a
candidate biomarker for lifestyle changes as well as the subsequent risk of mortality.
Keywords: Chronic inflammation, Prognosis, Biological ageing, Biomarker, Risk, Lifestyle change, Impact, Diet, Smoking,
Exercise
Background
Lifestyle intervention is an integral part of the manage-
ment of common chronic diseases, including cardiovas-
cular disease (CVD), type 2 diabetes, and chronic
obstructive pulmonary disease [1–3]. Achieving and
maintaining a healthy lifestyle is challenging and the
benefit is often merely an abstract reduction in the risk
of future disease, which may be insufficient motivation
for sustaining a healthy lifestyle. However, individuals’
knowledge about their risk improves the adherence to
lifestyle changes [4–7]. In the 1990s, inflammation was
recognized as a major risk factor for the development of
classical lifestyle diseases [8–11]. The gold standard for
measuring inflammation in healthy persons is C-reactive
protein (CRP) measured using a highly sensitive assay.
However, while CRP is a marker for CVD risk, an
indicator for mortality risk may be more appropriate
when assessing overall health. Also, CRP may lack
intra-individual stability [12–15]. Better biomarkers for
risk stratification may lead to more appropriate lifestyle
interventions and, thus, prevention of disease.
The urokinase plasminogen activator receptor (uPAR)
is expressed on activated immune cells and involved in
cell adhesion and migration, proliferation and invasion
through degradation of the extracellular matrix [16].
Under inflammatory conditions, uPAR is released from
the cell surface generating a soluble form of the receptor
(suPAR) with intrinsic chemotactic properties [17].
suPAR is a stable biomarker, both in vivo and in vitro
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[18, 19], and is positively correlated with labile
pro-inflammatory cytokines such as IL-1β and TNF-α as
well as with C-reactive protein [20]. Elevated levels are
associated with increased risk of CVD, type 2 diabetes,
chronic kidney disease, cancer, and premature death in
the general population [21–24]. We have previously
shown that suPAR levels are associated with lifestyle
[25], but it is currently unknown if lifestyle changes are
also reflected in subsequent suPAR measurements and if
such changes affect an individual’s mortality risk. If so,
suPAR could be used for guiding lifestyle changes,
similar to pharmacological interventions against
hypercholesterolemia or hypertension. To address
these questions, we investigated if lifestyle changes
during a 5-year period affected suPAR levels in a ran-
domized, population-based study. Furthermore, we
aimed to investigate if the resultant suPAR levels
were associated with mortality.
Results
Population characteristics
The study included 3225 individuals with suPAR measured
at baseline and at 5-year follow-up (see Fig. 1 and Methods
for details on study flow). From baseline to the 5-year visit,
11% of participants adopted a healthy diet, about 8% quit
smoking, and 5% fewer had a low level of physical activity
(Table 1). Alcohol consumption was stable, with about 15%
drinking more than recommended both at baseline and at
5 years. A baseline comparison with the participants who
did not have paired suPAR measurements available (n =
3473) showed a higher proportion of females (53.0% vs.
49.4%, P = 0.003), younger age (45.6 years vs. 46.4 years,
P < 0.001), and more daily smokers (43.3% vs. 28.6%,
P < 0.001) among non-participants.
suPAR changes from baseline to the 5-year visit
The median baseline suPAR (suPAR0) was 3.08 ng/ml
(IQR 1.29) for men and 3.44 ng/ml (IQR 1.46) for
women, and the median 5-year suPAR (suPAR5) was
3.29 ng/ml (IQR 1.36) for men and 3.66 ng/ml (P <
0.0001, IQR 1.35) for women. suPAR increased signifi-
cantly over the 5 year period with a similar increase in
both men (6.6%, IQR 42.0, P < 0.0001) and women
(6.0%, IQR 41.7, P < 0.0001).
Diet
In univariate analyses, the median suPAR increase
was significantly higher for those with an unhealthy
5-year diet compared with a healthy diet (Table 2,
Fig. 2a). To isolate the effect of lifestyle habits on
suPAR changes by taking into account confounding,
models with appropriate adjustments were con-
structed. Briefly, suPAR5 was modelled as a function
of age, sex, suPAR0, and lifestyle by multiple linear
Paired suPAR measurements
& valid smoking history
n=3,225
Did not participate
n=1,860
5-year follow-up
n=3,678
Inter99 study population
n=61,301
Reference population
n=48,285
Randomized to intervention
n=13,016
Participated at baseline
n=6,784
suPAR measured at baseline
n=5,538
suPAR not measured
n=1,246
suPAR measured at 5 years,
not at baseline
n=725
suPAR measured at 5 years
n=3,311
Misreported smoking habits*
n=86
suPAR not re-measured
n=367
5-year suPAR measurement
for survival analyses
n=3,950
Fig. 1 Flow of study participants. The “misreported smoking” group includes the one participant who was a never smoker at baseline and daily
smoker at the 5-year visit.
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regression. The back-transformed estimates are inter-
preted as the percent suPAR change associated with
each variable (Table 3). In Model 1, one life style
variable was included at a time, whereas in Model 2,
all four lifestyle variables were mutually adjusted (see
Methods for details on the modelling strategy). When
adjusted for suPAR0, age, and sex (Table 3, Model 1),
an unhealthy diet was associated with significantly
higher suPAR5 when compared with a healthy diet.
With additional adjustments for the intervention
group and the other lifestyle factors, the effect was
attenuated, but still significant (Table 3, Model 2).
Smoking
The 238 participants who quit daily smoking since base-
line had a median suPAR decrease of 9.1% compared
with an 8.1% increase among never smokers (Table 2,
Fig. 2b). In Model 1, smoking habits were strongly asso-
ciated with suPAR5 levels, with continuous daily smokers
having significantly higher suPAR compared with the
other categories (Table 3, Model 1). No significant differ-
ence was observed between never smokers and occa-
sional smokers (Table 3, Model 1). Interestingly, those
who quit daily smoking had suPAR5 levels comparable
to never smokers (daily➔quit vs. never, P = 0.11). The
Table 1 Baseline- and 5-year characteristics
Baseline 5-year visit
Mean or N (SD) or % Mean or N (SD) or %
Demographics
Age (years) 46.4 (7.8) 51.8 (7.8)
Male sex, no. 1632 50.6 – –
Risk factors
BMI (kg/m2) 26.0 (4.3) 26.4 (4.4)
Total cholesterol (mmol/l) 5.47 (1.0) 5.48 (1.0)
LDL cholesterol (mmol/l) 3.45 (0.9) 3.34 (0.9)
HDL cholesterol (mmol/l) 1.45 (0.4) 1.57 (0.4)
Triglyceride (mmol/l) 1.28 (1.1) 1.31 (1.0)
Systolic blood pressure (mmHg) 130.0 (16.7) 128.8 (16.4)
Diastolic blood pressure (mmHg) 82.5 (11.3) 80.9 (10.3)
Lifestyle
Diet, no. 3133 3165
Healthy 481 15.4 834 26.4
Average 2200 70.2 2053 64.9
Unhealthy 452 14.4 278 8.8
Smoking, no. 3201 3210
Never 1333 41.6 1333 41.5
Former 828 25.9 784 24.4
Occasional 125 3.9 113 3.5
Quit – – 271 8.4
Daily 915 28.6 709 22.1
Alcohol intake, no. 3114 3069
Abstinent 269 8.6 257 8.4
Within recommendations 2379 76.4 2380 77.5
Overuse 466 15.0 432 14.1
Physical activity, no. 3172 3193
Low activity 635 20.0 485 15.2
Light activity 1971 62.1 2047 64.1
Moderate activity 528 16.6 626 19.6
High activity 38 1.2 35 1.1
Baseline and 5-year characteristics of the main study sample with paired suPAR measurements (n = 3225). Abbreviations: SD standard deviation
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additional adjustments in Model 2 did not affect the es-
timates (Table 3, Model 2).
Alcohol
Alcohol consumption was not significantly associated
with suPAR changes in univariate analyses (Table 2).
In Model 1, alcohol overuse in men was associated
with higher suPAR5 when compared with a moderate
intake (P = 0.022). In women, abstinence was associ-
ated with higher suPAR5, with no difference between
overuse and moderate intake (Table 3, Model 1). In
the fully adjusted Model 2, only the association for
women remained.
Physical activity
The univariate analysis showed a non-significant trend
towards less of an increase in suPAR with higher phys-
ical activity (Table 2, Fig. 2c). In adjusted analyses, low
physical activity was significantly associated with higher
suPAR5 levels (Table 3, Model 1). In Model 2, the effect
was attenuated, but still significant (Table 3, Model 2).
Model control
To visualize the quality of the multiple linear regression
models, predicted suPAR5 values were generated using the
final Model 2 (without alcohol). Plotting the model predic-
tions against the actual suPAR5 values (Fig. 3) showed fair
Table 2 Median suPAR change from baseline to the 5-year visit stratified according to 5-year lifestyle
N suPAR0 (IQR) suPAR5 (IQR) % increase (IQR) P-value
All participants 3225 3.26 (1.41) 3.48 (1.39) 6.3 (41.8)
Diet rating
Unhealthy 278 3.31 (1.70) 3.77 (1.86) 10.8 (44.6)
Average 2053 3.27 (1.43) 3.48 (1.41) 6.2 (41.1)
Healthy 834 3.23 (1.29) 3.38 (1.26) 3.9 (43.3) 0.11
Smoking
Daily
➔Daily 642 4.09 (1.83) 4.39 (2.07) 7.0 (40.5)
➔Occasional 33 3.25 (1.47) 3.62 (1.77) −7.8 (42.9)
➔Quit 238 3.85 (2.05) 3.40 (1.31) −9.1 (46.5)
Never/occasional/former
➔Daily 64 3.15 (1.37) 3.55 (1.74) 16.8 (43.8)
➔Occasional 79 3.31 (1.07) 3.24 (0.96) 1.0 (40.2)
➔Former 781 3.09 (1.06) 3.30 (1.15) 5.5 (42.5)
➔Never 1317 3.05 (1.15) 3.30 (1.14) 8.1 (40.9)
➔Quit 33 3.07 (0.93) 3.47 (1.03) 13.0 (40.4) < 0.001
Alcohol intake, men
Abstinent 92 3.32 (1.79) 3.30 (1.24) −0.6 (48.6)
Within recommendations 1207 3.05 (1.23) 3.26 (1.33) 7.2 (41.2)
Overuse 285 3.14 (1.36) 3.38 (1.39) 8.1 (43.3) 0.063
Alcohol intake, women
Abstinent 165 3.50 (1.74) 3.89 (1.65) 10.8 (49.6)
Within recommendations 1173 3.42 (1.44) 3.60 (1.29) 5.3 (41.1)
Overuse 147 3.41 (1.47) 3.62 (1.49) 5.9 (42.9) 0.22
Physical activity
Low activity 485 3.50 (1.60) 3.70 (1.66) 8.5 (42.4)
Light activity 2047 3.27 (1.40) 3.49 (1.39) 6.1 (42.2)
Moderate activity 626 3.15 (1.24) 3.35 (1.25) 5.0 (41.0)
High activity 35 2.81 (0.78) 2.79 (0.59) 3.5 (49.4) 0.47
Median suPAR0, suPAR5, and % suPAR change from baseline to the 5-year visit stratified according to 5-year lifestyle. ➔: indicates the interaction between
baseline- and 5-year smoking habits. P-values from the Kruskal-Wallis test performed on the % suPAR change. Abbreviations: CI: confidence interval; IQR:
interquartile range; suPAR0: baseline suPAR; suPAR5: 5-year suPAR
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Fig. 2 Median suPAR at baseline and at the 5-year visit stratified according to diet (a), smoking (b), and physical activity (c)
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agreement between the actual and predicted suPAR5.
However, the model systematically over-estimated low
suPAR5 values and under-estimated high values.
5-year suPAR level and mortality
All 3950 participants with a suPAR5 measurement and
complete smoking history were followed for a mean of 6.1
years after the 5-year visit, during which 82 subjects
(2.08%) died. When stratifying the participants according to
age- and sex-specific suPAR5 median splits, the group with
high suPAR5 (mean 4.73 ng/ml, range 3.09–15.4 ng/ml) had
a mortality of 3.8% compared with 1.6% in the low suPAR5
group (mean 2.93 ng/ml, range 0.90–3.76 ng/ml), P < 0.001
(Fig. 4). In Cox regression analyses, the hazard ratio (HR)
per suPAR5 doubling was 2.42 (95% CI: 1.58–3.72) when
adjusted for age and sex. Even with additional adjustments
for all four lifestyle factors, the HR for mortality for a
suPAR5 doubling remained significant (Table 4). Only
5-year dietary habits had a significant impact on mortality
(HR 0.37 for a healthy diet vs. an unhealthy diet, P = 0.04)
Table 3 Percent impact of 5-year lifestyle on 5-year suPAR
5-year follow-up
Model 1 Model 2
% more suPAR5 95% CI % more suPAR5 95% CI
Demographics
Age, men (per 5 years) 2.9*** (2.0–3.8) 3.1*** (2.3–4.0)
Age, women (per 5 years) 0.2 (−0.6–1.1) 0.7 (−0.09–1.6)
Female sex (vs. male sex) 6.9*** (4.8–9.0) 8.0*** (5.9–10.2)
Lifestyle
Diet (vs. healthy)
Unhealthy 11.3*** (7.2–15.5) 5.9** (2.0–10.0)
Average 3.8** (1.5–6.1) 1.9 (−0.3–4.2)
Smoking baseline➔5-years
(vs. never➔never)
Daily
➔Daily 18.8*** (15.7–21.9) 17.6*** (14.5–20.8)
➔Occasional 3.1 (−5.8–12.9) 4.3 (−4.8–14.1)
➔Quit −3.1 (−6.6–0.5) −3.0 (−6.5–0.7)
Never/former/occasional
➔Daily 10.2** (3.2–17.7) 8.7* (1.8–16.1)
➔Occasional −3.5 (−9.1–2.4) −3.6 (−9.2–2.3)
➔Former −1.4 (− 3.7–0.9) −1.3 (−3.5–1.1)
➔Quit 4.6 (−4.4–14.5) 5.9 (−3.2–16.0)
Physical activity (vs. high activity)
Low activity 17.5** (7.0–29.0) 12.8** (3.1–23.5)
Light activity 11.4* (1.8–22.0) 8.8 (−0.4–18.9)
Moderate activity 9.2 (−0.4–19.7) 7.7 (−1.5–17.8)
Alcohol intake, men (vs. recommended)
Abstinent 0.7 (− 4.9–6.6) −1.0 (− 6.4–4.7)
Overuse 4.2* (0.6–7.8) 2.7 (−0.8–6.2)
Alcohol intake, women (vs. recommended)
Abstinent 7.1** (2.5–11.9) 6.6* (2.1–11.3)
Overuse 1.5 (−3.0–6.3) −0.9 (− 5.2–3.7)
The effect of lifestyle on suPAR5 adjusted for suPAR0
Model 1: log2(suPAR5) ~ age, sex, log2(suPAR0) + one lifestyle factor per line (n = 3069–3225)
Model 2: log2(suPAR5) ~ age, sex, log2(suPAR0), intervention intensity, diet, smoking, and physical activity (n = 3166, R
2 = 0.326). For categorical variables, the
parenthesis indicates the reference value. Model 2 with alcohol was run separately because of missing observations (n = 3044, R2 = 0.331)
➔: indicates the interaction between baseline and 5-year smoking habits, e.g. never (baseline)➔never (5-year). The horizontal line indicates the split between
Model 2 without (above) and with (below) alcohol habits. *: P < 0.05, **: P < 0.01, ***: P < 0.001. Abbreviations: CI: confidence interval; suPAR0: baseline suPAR;
suPAR5: 5-year suPAR
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in the fully adjusted model; whereas, the effect of 5-year
smoking habits was non-significant when suPAR was in-
cluded in the model (data not shown).
Discussion
In this large study of individuals from the general popula-
tion measured at baseline and after 5 years—and followed
for 6 years hereafter—we demonstrated that major lifestyle
habits (diet, smoking, alcohol, and physical activity) are
reflected in the inflammatory biomarker suPAR, with
healthy habits generally associated with lower suPAR and
unhealthy habits with higher suPAR. The absolute suPAR5
level, in turn, was strongly associated with mortality, even
when adjusted for the lifestyle habits. From baseline to the
5-year visit, suPAR increased by a median of 6%. Un-
healthy lifestyle habits were generally associated with a lar-
ger suPAR increase compared to healthy lifestyle habits in
univariate analyses.
Studies in both the general population and patient
studies have shown that suPAR is a strong marker for
mortality. The current study suggests that suPAR is a
modifiable risk factor, an early warning signal and not a
death sentence. But what does the suPAR level reflect?
suPAR shows a positive correlation with CRP [21]. How-
ever, suPAR and CRP seem to reflect different aspects of
inflammation, and it has been proposed that suPAR re-
flects cellular inflammation while CRP reflects metabolic
inflammation [26]. While CRP is rapidly up- and
down-regulated, suPAR show stable kinetics with limited
circadian fluctuation [18, 27] and, as shown in the
current paper, with a high correlation over a 5-year
period. Furthermore, suPAR is positively correlated with
pro-inflammatory cytokines, including IL-1β, IL-6, and
TNF-α [28], all of which are upregulated during the
process of inflammaging [29]. On a transcriptional level,
activation of pattern recognition receptors, i.e., Toll-
like-receptors and NOD-like receptors (e.g. by smoking
[30]), as well as proinflammatory cytokine receptors acti-
vate the transcription factors NF-κB and AP-1 that bind
the promoter region of the gene for uPAR/suPAR,
PLAUR, and upregulate expression of uPAR [31]. In
contrast, stimulation of whole blood with suPAR has lit-
tle or no effect on the expression of inflammatory cyto-
kines [32]. Hence, suPAR may be a less functionally
active biomarker and therefore allowed to freely circu-
late, in contrast to most proinflammatory cytokines with
strong local acting immune effects.
It could be speculated that suPAR, due to its stability
and upregulation during states of even slightly increased
immune activity, is a marker of the overall immune acti-
vation and inflammatory processes in an individual and
therefore a marker of chronic inflammation. While
cleavage of uPAR to suPAR may simply be a way to
downregulate uPAR activity, suPAR has been suggested
to play a role in chemotaxis [33], neutrophil efferocytosis
[34], and angiogenesis [35], although the direct immuno-
logical effects of suPAR are less well understood.
Whether suPAR is reflective of disease processes or is
causing disease is an ongoing discussion [36]. Recent
work has shown that suPAR is causal of kidney disease
[37], but this observation does not explain why suPAR
also predict development of a range of other diseases. In
Fig. 3 Predicted 5-year suPAR values from Model 2 (log2(suPAR5-year) ~ log2(suPARbaseline), sex, age, intervention group, diet, smoking, physical
activity) plotted against the actual 5-year suPAR values. Note the logarithmic axes. Thin line: indicates agreement
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any case, whether suPAR is causal or reflects a disease
process, our current study corroborates elevated suPAR
as a marker of negative outcome but add the effect of
lifestyle and lifestyle interventions on suPAR levels.
To show the actual effect of the four lifestyle factors
on suPAR5 levels, we modeled the suPAR5 values ad-
justed for suPAR0, demographic factors, and the four
lifestyle factors to neutralize the regression towards the
mean. Interestingly, baseline diet, physical activity, and
alcohol consumption had no impact on suPAR5, prob-
ably because the baseline habits are adequately reflected
in suPAR0. In contrast, a smoking history was necessary
for the model, because smoking is likely to be the life-
style factor with the highest impact on suPAR level. Des-
pite the high impact of daily smoking on suPAR levels,
we found no difference in suPAR level change between
never smokers and occasional smokers. We recently
found that a high degree of self-control is associated
with lower suPAR levels [38], which may in part explain
why occasional smoking is not associated with higher
suPAR levels. The fully adjusted model showed that
when comparing men identical at baseline, with the
same suPAR0, but with very different 5-year lifestyles,
the combination of unhealthy habits within all four life-
style areas at 5 years was associated with 44% higher
suPAR5 (1.059 × 1.176 × 1.027 × 1.128 = 1.44, estimates
from Table 3) when compared with healthy habits. The
model predictions (Fig. 3) indicate that this difference is
likely to be underestimated, probably because the as-
sumption of an independent effect of each lifestyle factor
is not realistic; instead, there may be a synergistic effect
of clustering several unhealthy or healthy habits.
When following the participants for approximately 6
years after the 5-year visit, the absolute suPAR5 level
was strongly associated with all-cause mortality. When
adjusted for suPAR5, smoking habits, alcohol consump-
tion, and physical activity had no effect on mortality.
Taken together, suPAR was a strong predictor of mortality
in this cohort, but the lifestyle habits that affect
suPAR were not. This finding is highly interesting, as it
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Fig. 4 Mortality after the 5-year visit stratified according to age- and sex-specific 5-year suPAR median splits. The insert indicates a zoom to the
0.00 to 0.04 mortality range. Low suPAR range: 0.90–3.76 ng/ml. High suPAR range: 3.09–15.4 ng/ml
Table 4 Hazard ratios for mortality per suPAR5 doubling
Adjustments N
(deaths)
HR per suPAR5 doubling
(95% CI)
None 3950 (82) 2.48 (1.64–3.76)
Sex, age 3950 (82) 2.42 (1.58–3.72)
Sex, age, smoking 3934 (82) 2.17 (1.35–3.48)
Sex, age, smoking, diet, exercise 3905 (80) 2.19 (1.35–3.54)
Sex, age, smoking, diet, exercise, alcohol 3734 (74) 2.03 (1.22–3.37)
Hazard ratio (95% CI) for all-cause mortality per doubling of suPAR5 with step-wise adjustments for sex, age, and 5-year lifestyles. Abbreviations: CI: confidence
interval; suPAR5: 5-year suPAR
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suggests that a given lifestyle modification’s impact on
mortality risk can be assessed by performing a subsequent
suPAR measurement. Further studies are needed to con-
firm that serial suPAR measurements can be used as a
guide for the “true” risk reduction of lifestyle changes.
This study has several strengths. The paired nature
of the suPAR measurements strongly supports the
causality between certain lifestyle habits and suPAR,
since any lifestyle changes always occurred before the
second suPAR measurement. The modeling frame-
work ensured that the effects of the lifestyle habits
were mutually adjusted, and regression towards the
mean was eliminated by adjusting for baseline suPAR.
Also, the effects of lifestyle found in this study are
generally in agreement with the baseline study results
[25]. The recording of mortality is highly accurate as
all deaths of persons living in Denmark are recorded
in national registries. All lifestyle habits were re-
corded via validated questionnaires.
A limitation of the study is that less than half of the par-
ticipants had available suPAR measurements both at base-
line and the 5-year visit, and the proportion of daily
smokers among participants was considerably lower. Thus,
it is likely that more resourceful and relatively healthy
persons participated in the 5-year visit. For self-reported
lifestyle habits, we were only able to exclude those misre-
ported for the obviously impossible combinations of smok-
ing habits (e.g. a daily smoker at baseline cannot be a never
smoker after 5 years). We suspect that social desirability
bias led to a systematic under-reporting of unhealthy habits.
It is also likely that certain combinations of lifestyle habits
affect suPAR in a synergistic way, as suggested by the sys-
tematical over- and under-estimation of high and low
suPAR levels, respectively.
Conclusion
We demonstrated that suPAR covaries with lifestyle
in a large general population cohort, with healthy
5-year lifestyle habits associated with lower suPAR
levels. The models indicate that serial suPAR mea-
surements can be interpreted using just one previous
measurement, information about current lifestyle, and
smoking history. For the almost four thousand sub-
jects with suPAR5 values, suPAR was highly predictive
of mortality during the next 6 years, irrespective of
their lifestyle. We propose that suPAR is a candidate
biomarker not only for lifestyle changes, but also for
the subsequent risk of mortality.
Methods
Charaterization of participants
The current study population consisted of participants
in a large population-based study, Inter99, which is
reported in detail elsewhere [25, 39, 40]. Briefly, 61,301
individuals from a general population, aged 30 to 60
years and living in the southwestern part of Copenhagen
were randomly selected to participate in the study.
There were 13,016 subjects randomized to the interven-
tion group and 6784 (52.5%) attended the clinic at base-
line. All participants received repeated individual
lifestyle counseling on smoking habits, physical activity,
alcohol consumption, and dietary habits, and the major-
ity (90%; high-intensity group A) were also offered re-
peated group-based lifestyle counseling. Participants in
the low-intensity group B (10%) only received repeated
individual lifestyle counseling.
From 1999 to 2000, 5538 participants (81.6%) had
suPAR measured at baseline (suPAR0) [25]. Five years
later in 2004–2005, they were invited to the 5-year visit:
3678 participated (66.4%), and 3311 (90.0%) had their
suPAR re-measured (suPAR5, Fig. 1). Eighty-five had an
invalid smoking history (e.g. never smoking at 5 years,
but daily smoking at baseline) and were excluded from
further analyses. The group of baseline never smokers
who reported daily smoking at 5 years only included one
participant who was also excluded. Thus, the study main
sample comprised 3225 participants. An additional 725
participants had suPAR5 measurements, but no suPAR0
measurement, and were included in the suPAR5 survival
analyses.
Assessments
The serum obtained in 1999–2000 (baseline) and in
2004–2005 (5-year) were collected the following way:
Three 7 ml Becton Dickinson tubes (no. 367789) were
filled with blood and centrifugated for 25 min at 1300G.
Serum was transferred to a Sarstedt tube (no. 60540012)
and stored at − 20 °C until measurement of suPAR. The
serum suPAR level was measured with the suPARnostic
ELISA (ViroGates A/S, Birkerød, Denmark) in 2011. Par-
ticipants with serum suPAR higher than 22 ng/ml (outside
assay range) or an increase from baseline to the 5-year
visit higher than 20 ng/ml were excluded (n = 5). All par-
ticipants answered a questionnaire on lifestyle and under-
went a physical examination at baseline and at the 5-year
visit. The methods used for measuring body mass index
(BMI), cholesterol, triglycerides, and blood pressure were
described by Jørgensen and coworkers [39]. Lifestyle was
self-reported. The dietary quality score (DQS-9) is vali-
dated and based on a one-week food diary where four
food groups (vegetables, fruit, fish, and fat) were given
points based on the degree of compliance with national
dietary recommendations, and the combined score was
categorized as “unhealthy”, “average”, or “healthy” diet
[41]. Self-reported smoking habits were registered
(“never”, “former”, “occasional”, or “daily” smokers)
and an extra category was created for those who quit
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smoking at the 5-year visit. Weekly self-reported con-
sumption of alcoholic beverages was converted into
units (12 g) of alcohol per week and categorized
according to national recommendations in 1999 as
“abstinent”, “within recommendations” (≤ 14 units/
week for women and ≤ 21 units/week for men) or
“overuse” (> 14 units/week for women and > 21 units/
week for men). Leisure time physical activity was re-
ported according to the categories by Saltin: mainly
reading or watching television or equivalent sedentary
activities (“low”); going for walks, biking, or equiva-
lent light activity for up to 4 h per week (“light”);
sport activities at least three times per week or an
equivalent amount of strenuous gardening or similar
(“moderate”); or competitive sports or long distance
running several times per week (“high”) [42].
Statistical analysis
The suPAR change from baseline to the 5-year visit
was calculated as the ratio of suPAR5/suPAR0 and
listed in Table 2 as the median percent suPAR
change. Differences in suPAR ratios were tested with
the Kruskal-Wallis test. For the adjusted models,
log2-transformed suPAR5 was modeled by multiple
linear regressions as a function of log2-transformed
suPAR0, demographic variables, and lifestyle variables.
The estimates were back-transformed by (2β–1) × 100
and interpreted as the percent difference in suPAR5.
All models were adjusted for suPAR0, sex, and age at
the 5-year visit, and they included the interaction be-
tween age and sex observed in the baseline study
[25]. The models with alcohol consumption as an
explanatory variable were analyzed separately because
of more missing observations for alcohol (n = 156),
and we allowed for the interaction between sex and
alcohol consumption observed in the baseline study.
Models with smoking included an interaction between
the 5-year smoking habits and dichotomized baseline
smoking habits (daily smoker or not daily smoker).
Tables 2 and 3 are stratified in accordance with these
interactions.
The survival analyses are Cox proportional hazards
models with death as the event, years after the
5-year visit as the time variable, and log2(suPAR5) as
the main explanatory variable. For the Kaplan Meier
plot, we generated sex- and age-specific (≤ 55 years
or > 55 years) suPAR5 median splits. All tests were
two-sided and interpreted at an α-level of 0.05. SAS
9.4 (SAS Institute, Cary, NC, USA) was used for
statistical analysis.
Modeling strategy
The interpretation of raw suPAR changes was hampered
by regression towards the mean, i.e. a high suPAR0 was
generally associated with a lower suPAR5 (Fig. 5). Conse-
quently, all models of suPAR5 were adjusted for suPAR0.
For each lifestyle variable (diet, smoking, alcohol, and
physical activity), models were fitted with 5-year and
baseline lifestyle interactions and 5-year and baseline
lifestyle without interactions. A significant interaction
was found for smoking (P = 0.014). For all other lifestyle
factors, only the 5-year lifestyle had an effect on suPAR5.
Fig. 5 The 5-year suPAR plotted against the baseline suPAR with linear trend line and Pearson’s correlation coefficient. Note the logarithmic axes.
Thick line: Loess line with 95% confidence interval. Thin line: indicates agreement
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We generated two model frameworks. In Model 1,
suPAR5 was modeled as a function of age, sex,
suPAR0, and one lifestyle variable at a time. In Model
2, all four lifestyle factors and the intervention inten-
sity were included in the same model (estimates for
intervention intensity not shown as they had no
significant effect on suPAR).
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